This site provides INTERCEPT product information for International audiences Select your region
The INTERCEPT™ Blood System has been shown to inactivate CMV in platelet components, as demonstrated through infectivity reduction studies and animal models. Combined with the use of leukoreduced products (as is the case in many countries), this eliminates the need for the selection of CMV-negative units by serology testing.